Parkinson’s Disease Clinical Trial Pipeline Gains Momentum: 130+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2026” report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Parkinson’s Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insight
Key Takeaways from the Parkinson’s Disease Pipeline Report
- On February 09, 2026, Hoffmann-La Roche conducted a phase III study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson’s disease (PD) on stable symptomatic monotherapy with levodopa.
- On January 23, 2026, Kenai Therapeutics initiated a phase 1b/2a clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.
- DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 130+ active players working to develop 150+ pipeline therapies for Parkinson’s Disease treatment.
- The Parkinson’s Disease Companies such as Annovis Bio, Cerevel Therapeutics, Roche, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune and others.
- Promising Parkinson’s Disease Pipeline Therapies such as KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others
Stay informed about the cutting-edge advancements in Parkinson’s Disease treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Parkinson’s Disease Clinical Trials Assessment
The Parkinson’s Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Parkinson’s Disease Pipeline Report also highlights the unmet needs with respect to the Parkinson’s Disease.
Parkinson’s Disease Overview
Parkinson’s disease (PD) is a chronic and progressive neurological disorder that primarily affects movement. It is characterized by the gradual loss of dopamine-producing neurons in the substantia nigra, a region of the brain crucial for movement control. PD typically manifests in individuals over the age of 60, though younger onset is possible. It is the second most common neurodegenerative disorder after Alzheimer’s disease. The progression of symptoms can vary widely among individuals, making the disease challenging to predict and manage.
Parkinson’s Disease Emerging Drugs Profile
- Buntanetap: Annovis Bio
Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients. Currently, the drug is in Phase III trial for the treatment of Parkinson’s disease.
- Tavapadon: AbbVie
Tavapadon is the first and only selective D1/D5 receptor partial agonist in development for Parkinson’s disease and is currently being studied as a once-daily medicine for use as both a monotherapy and as an adjunctive therapy to LD. Tavapadon is designed to selectively and optimally activate D1/D5 receptors to potentially provide the right balance of motor control, safety and tolerability for patients. By selectively activating D1/D5 dopamine receptors along the nigrostriatal pathway, tavapadon has the potential to offer the right balance of dopamine signaling to improve motor control while avoiding D2/D3 overstimulation, which is believed to underlie many of the side effects of current dopamine agonists. Additionally, as a partial agonist with a 24-hour half-life enabling once-daily dosing, tavapadon may avoid hyper activation of the dopamine receptors, which can lead to troublesome dyskinesias. Currently, the drug is in Phase III trial for the treatment of Parkinson’s disease.
- Prasinezumab: Roche
Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson’s disease. It has been tested in preclinical models of synuclein-related disease and has shown a reduction of neurodegeneration. Currently, the drug is in Phase II trial for the treatment of Parkinson’s disease.
- GT 02287: Gain Therapeutics
GT-02287, is an allosteric regulator of GCase and is in development for the treatment of PD, with GBA1-PD as the lead indication. The orally administered, brain-penetrant small molecule restores the function of GCase. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced cellular stress in the endoplasmic reticulum, improved lysosomal function and mitochondrial function, reduced toxic glycosphingolipids, aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function. Currently, the drug is in Phase I trial for the treatment of Parkinson’s disease.
- NNI 362: Neuronascent
NNI-362 is Neuronascent’s patented oral therapeutic aimed at reversing age-related disorders by producing new neurons to replace those lost in chronic neurodegenerative disorders and aging. NNI-362 has a unique mechanism of action (MOA) that provides safety and selectivity specifically for neuron regeneration, and was discovered through Neuronascent’s proprietary phenotypic screening program using human neural progenitors. This MOA takes advantage of the neural progenitors already in the aged brain to promote new neurons and protect them from degeneration in chronic diseases of the aged, specifically Alzheimer’s disease. New neuron regeneration from neural progenitors is a physiologic process in the brain, yet with aging and neurodegenerative disease there begins a pathological insufficiency in generating new neurons that survive to functionality. Thus, NNI-362 is aimed at reversing age-related neuron loss and restoring cognitive function in AD patients, and should also be useful for other disorders of the elderly, including Parkinson’s disease and age-related hearing loss. Currently, the drug is in Preclinical trial for the treatment of Parkinson’s disease.
Learn more about Parkinson’s Disease Drugs opportunities in our groundbreaking Parkinson’s Disease research and development projects @ Parkinson’s Disease Unmet Needs
The Parkinson’s Disease Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
- Parkinson’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.
Parkinson’s Disease Companies
Annovis Bio, Cerevel Therapeutics, Roche, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune and others.
Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Parkinson’s Disease Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Stay informed about how we’re transforming the future of Cardiovascular Diseases @ Parkinson’s Disease Market Drivers and Barriers, and Future Perspectives
Scope of the Parkinson’s Disease Pipeline Report
- Coverage- Global
- Parkinson’s Disease Companies– Annovis Bio, Cerevel Therapeutics, Roche, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune and others.
- Parkinson’s Disease Pipeline Therapies- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others
- Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Parkinson’s Disease Pipeline on our website @ Parkinson’s Disease Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Parkinson’s Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Parkinson’s Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Buntanetap: Annovis Bio
- Mid Stage Products (Phase II)
- Prasinezumab: Roche
- Early Stage Products (Phase I)
- GT 02287: Gain Therapeutics
- Preclinical and Discovery Stage Products
- NNI 362: Neuronascent
- Inactive Products
- Parkinson’s Disease Key Companies
- Parkinson’s Disease Key Products
- Parkinson’s Disease- Unmet Needs
- Parkinson’s Disease- Market Drivers and Barriers
- Parkinson’s Disease- Future Perspectives and Conclusion
- Parkinson’s Disease Analyst Views
- Parkinson’s Disease Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insight
